Login to Your Account



Apogenix biomarker pinpoints responders to glioblastoma drug

By Cormac Sheridan
Staff Writer

Monday, January 13, 2014
europe_resized.jpg

Apogenix GmbH is meeting officials from three of Europe’s leading national drug regulators in the coming weeks to evaluate whether they will support a bid to obtain conditional marketing approval for its glioblastoma drug APG101, following a fresh biomarker analysis, which shows that the therapy offers likely responders a 10-month survival benefit. The Heidelberg, Germany-based firm unveiled the new analysis at the J.P. Morgan Healthcare Conference in San Francisco, where it is drumming up interest from investors and potential partners alike.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription